Glido MP1 Tablet ER is a combination oral antidiabetic medication containing Glimepiride (1mg), Metformin (500mg), and Pioglitazone (15mg), formulated for extended release to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose uptake and utilization. Pioglitazone, a thiazolidinedione, further enhances insulin sensitivity in adipose tissue, muscle, and the liver by activating peroxisome proliferator-activated receptor gamma (PPAR-γ). The combination targets multiple pathophysiological defects of type 2 diabetes, providing a complementary mechanism of action to achieve optimal glycemic control. Glido MP1 Tablet ER is indicated as an adjunct to diet and exercise for patients inadequately controlled on monotherapy or dual therapy. Extended-release formulation allows for once-daily dosing, improving patient compliance. Caution is advised in patients with renal or hepatic impairment, heart failure, or a history of lactic acidosis. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended. Adverse effects may include hypoglycemia, gastrointestinal disturbances, weight gain, and edema. This medication should be used under medical supervision with appropriate lifestyle modifications.